MetLife Stock Gains 24% YTD, Defies Sector Downturn

MetLife Inc. (MET) shares advanced significantly in the first half of 2026, with the stock posting a 24% year-to-date gain as of June 29. This performance substantially outpaces the broader S&P 500 index, which returned approximately 15% over the same period. The life insurer's rally is attributed to strong fundamental execution and a strategic pivot toward higher-growth business segments. CNBC reported the momentum on June 29, highlighting that the market may not have fully priced in these developments.

Context — why this matters now

MetLife's current rally contrasts sharply with its performance during the 2022 rising rate environment, when the stock declined 11% as fixed income portfolio losses pressured earnings. The current macro backdrop features the 10-year Treasury yield stabilizing near 4.2%, providing a more favorable environment for insurers' investment income. The catalyst for MetLife's outperformance is its successful execution of a multi-year strategic shift. The company has deliberately reduced its exposure to traditional volatile life insurance products and increased its focus on higher-margin group benefits and retirement solutions.

This repositioning accelerated following the spinoff of Brighthouse Financial in 2017, which allowed MetLife to shed capital-intensive annuity businesses. The company's 2025 investor day outlined specific targets for growing its capital-light businesses to over 60% of earnings by 2027. Current results indicate the company is tracking ahead of this schedule, with group benefits now contributing 47% of operating earnings compared to 38% just two years ago.

Data — what the numbers show

MetLife's stock closed at $78.42 on June 28, representing a 24.1% gain since December 31, 2025. The company's market capitalization now stands at $60.4 billion. This performance significantly outpaces the S&P 500 Insurance Index, which gained only 9.2% year-to-date. MetLife's price-to-earnings ratio of 9.8 remains below the sector median of 11.2, suggesting valuation expansion potential.

The company reported first-quarter 2026 adjusted earnings per share of $2.15, beating consensus estimates by $0.12. Premiums, fees and other revenues reached $16.8 billion for the quarter, up 6% year-over-year. Notably, adjusted return on equity improved to 14.2% from 12.8% in the year-ago period. Book value per share grew to $68.21, a 7% increase from the previous year.

Metric	Q1 2026	Q1 2025	Change
Group Benefits Revenue	$5.2B	$4.7B	+10.6%
Retirement Solutions Revenue	$3.8B	$3.6B	+5.6%
International Revenue	$3.1B	$3.0B	+3.3%

Analysis — what it means for markets / sectors / tickers

MetLife's outperformance creates positive spillover effects for other insurers with similar business mixes. Prudential Financial (PRU) gained 18% year-to-date as investors anticipate similar strategic benefits, while Unum Group (UNM) advanced 22% on group disability insurance momentum. The rally pressures short positions that constituted 2.3% of MetLife's float as of mid-June, potentially forcing covering rallies.

The primary risk to the thesis is potential margin compression in group benefits if medical cost trends exceed expectations. Medical inflation currently runs at 4.8% annually, above the 3.5% assumed in most pricing models. Institutional flow data shows pension funds and insurance dedicated funds have been net buyers of MetLife shares, with $480 million in net inflows over the past quarter versus sector outflows of $210 million.

Outlook — what to watch next

Second-quarter 2026 earnings on July 24 represent the immediate catalyst, with analysts projecting EPS of $2.08 on revenues of $17.1 billion. The Federal Reserve's July 30 meeting will provide crucial guidance on interest rate policy, which directly impacts MetLife's investment portfolio yields. Key technical levels include resistance at $81.50, representing the March 2025 high, and support at $74.20, the 50-day moving average.

Should MetLife deliver another earnings beat and maintain its full-year guidance of $8.40-8.80 EPS, the stock could test the $85 level. A break above $81.50 on volume exceeding the 90-day average of 4.2 million shares would confirm the bullish technical structure. Conversely, a miss on earnings or downward revision to guidance could trigger a pullback to the $70-72 support zone.

Frequently Asked Questions

What does MetLife's performance mean for dividend investors?

MetLife currently offers a 3.1% dividend yield, with a payout ratio of 28% of earnings. The company has increased its dividend for 11 consecutive years, with the most recent hike being 6% in February 2026. Strong earnings growth supports continued dividend increases, making MET attractive for income investors seeking exposure to financial services without the volatility of bank stocks.

How does MetLife's valuation compare to historical levels?

MetLife trades at 9.8 times forward earnings, below its 5-year average of 10.4 times. The stock's price-to-book ratio of 1.15 remains modest compared to the financial sector median of 1.35. Historical analysis shows that when MET's P/E multiple expands above 11 during periods of ROE improvement, the stock typically delivers 20%+ annualized returns over the subsequent 18 months.

What regulatory changes affect life insurers like MetLife?

The National Association of Insurance Commissioners adopted updated reserving standards (VM-21) in 2025, requiring insurers to hold more capital against long-duration products. MetLife completed its transition to these standards ahead of schedule, giving it a competitive advantage over peers still adapting. The new rules favor companies with stronger group benefits businesses, which require less capital than traditional life products.

Bottom Line

MetLife's strategic pivot to capital-light businesses drives outperformance that may continue through 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.